Research output per year
Research output per year
Fingerprint
Dive into the research topics where Ilari Mäki-Opas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma
Mäki-Opas, I., Hämäläinen, M., Moilanen, E. & Scotece, M., 2023, In: Arthritis Research and Therapy. 25, 1, 12.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile3 Downloads (Pure) -
TRPA1 Mediates Contact Hypersensitivity Induced by 2,4-Dinitrochlorobenzene
Mäki-Opas, I., Hämäläinen, M., Moilanen, L. J., Sood, H., Leppänen, T., Kummola, L., Junttila, I. S., Lehtimäki, L. & Moilanen, E., 2023, In: Journal of Investigative Dermatology. 143, 6, p. 1104-1108.e4Research output: Contribution to journal › Letter › Scientific
Open AccessFile -
Pyrazine-Fused Triterpenoids Block the TRPA1 Ion Channel in Vitro and Inhibit TRPA1-Mediated Acute Inflammation in Vivo
Mäki-Opas, I., Hämäläinen, M., Moilanen, L. J., Haavikko, R., Ahonen, T. J., Alakurtti, S., Moreira, V. M., Muraki, K., Yli-Kauhaluoma, J. & Moilanen, E., 2019, In: ACS Chemical Neuroscience. 10, 6, p. 2848-2857Research output: Contribution to journal › Article › Scientific › peer-review
3 Citations (Scopus) -
Natural Stilbenoids Have Anti-Inflammatory Properties in Vivo and Down-Regulate the Production of Inflammatory Mediators NO, IL6, and MCP1 Possibly in a PI3K/Akt-Dependent Manner
Eräsalo, H., Hämäläinen, M., Leppänen, T., Mäki-Opas, I., Laavola, M., Haavikko, R., Yli-Kauhaluoma, J. & Moilanen, E., 2018, In: Journal of natural products. 81, 5, p. 1131-1142Research output: Contribution to journal › Article › Scientific › peer-review
26 Citations (Scopus)
Activities
- 7 Conference presentation
-
TRPA1 mediates DNCB-induced allergic contact dermatitis
Ilari Mäki-Opas (Speaker), Mari Hämäläinen (Contributor), Lauri Moilanen (Contributor), Heini Sood (Contributor), Tiina Leppänen (Contributor), Lauri Lehtimäki (Contributor) & Eeva Moilanen (Contributor)
24 Aug 2022 → 26 Aug 2022Activity: Talk or presentation › Conference presentation
-
TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1 deficient mice in experimentally induced scleroderma
Ilari Mäki-Opas (Speaker), Mari Hämäläinen (Contributor), Eeva Moilanen (Contributor) & Morena Scotece (Contributor)
5 May 2022 → 6 May 2022Activity: Talk or presentation › Conference presentation
-
TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1 deficient mice in experimentally induced scleroderma
Ilari Mäki-Opas (Speaker), Mari Hämäläinen (Contributor), Eeva Moilanen (Contributor) & Morena Scotece (Contributor)
25 Nov 2021 → 26 Nov 2021Activity: Talk or presentation › Conference presentation
-
TRPA1 mediates DNCB-induced allergic contact dermatitis
I Mäki-Opas (Contributor), M Hämäläinen (Contributor), LJ Moilanen (Contributor), H Sood (Contributor), T Leppänen (Contributor), L Lehtimäki (Contributor) & E Moilanen (Contributor)
29 Nov 2019Activity: Talk or presentation › Conference presentation
-
CAMP enhancing drugs salbutamol and rolipram augment the alternative activation of murine macrophages through MKP-1
I Mäki-Opas (Contributor), M Scotece (Contributor), M Hämäläinen (Contributor) & E Moilanen (Contributor)
15 Sept 2019Activity: Talk or presentation › Conference presentation